Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory A. Grabowski, Margaret A. Heisel‐Kurth et al.|American Journal of Hematology|2012Cited by 62
Early access experience with VPRIV®: Recommendations for ‘core data’ collectionDerralynn Hughes, Neal J. Weinreb, Moeen Al-Sayed et al.|Blood Cells Molecules and Diseases|2010Cited by 4
Safety and efficacy of long-term enzyme replacement therapy with velaglucerase alfa in patients with type 1 Gaucher disease transitioned from imigluceraseDeborah Elstein, Ari Zimran, Pilar Giraldo et al.|Molecular Genetics and Metabolism|2014Cited by 1
Efficacité et tolérance à long terme d’une enzymothérapie substitutive la vélaglucérase alfa, chez les patients atteints de la maladie de gaucher de type 1 qui ont switché de l’imiglucéraseDeborah Elstein, Ari Zimran, Pilar Giraldo et al.|La Revue de Médecine Interne|2015Cited by 0